El Mahmoud R, Le Feuvre C, Le Quan Sang K H, Helft G, Beygui F, Batisse J P, Metzger J P
Institut de cardiologie, groupe hospitalier La Pitié-Salpêtrière, Paris.
Arch Mal Coeur Vaiss. 2003 Dec;96(12):1157-61.
Recent studies have suggested that an oral dose of acetylcysteine could play a prophylactic role in the prevention of nephrotoxicity from iodine contrast media in patients affected by chronic renal failure. Between June 2001 and September 2002 we selected 120 patients with a basal plasma creatinine level greater than 1.36 mg/dl investigated by coronary angiography. The treatment group included 60 patients who received 600 mg of acetylcysteine in the morning and evening before the day of the examination together with intravenous saline hydration. The control group patients received hydration alone. The clinical characteristics of the groups were comparable as well as the basal plasma creatinine level: 2.01+/-1.1 mg/dl in the acetylcysteine group and 1.81+/-0.69 in the control group. The plasma creatinine level was measured 24 and 48 hours after coronary angiography. The respective changes in plasma creatinine level at 24 and 48 hours were 0.12+/-0.29 and 0.02+/-0.29 mg/dl in the acetylcysteine group and 0.06+/-0.29 and 0.07+/-0.43 mg/dl in the control group (NS). Acute renal failure caused by the contrast medium, defined by an increase of 25% in the plasma creatinine level compared to the basal value, occurred in 3 patients from the acetylcysteine group and 2 patients from the control group. The only predictive factor for acute renal failure was the quantity of contrast medium (316+/-141 vs 173+/-115 ml, p<0.05). In conclusion, acute renal failure caused by contrast medium is rare in sufficiently hydrated patients with moderate chronic renal failure when a low dose of contrast medium is used. Our study does not confirm a prophylactic effect of acetylcysteine in the prevention of nephrotoxicity from contrast media following coronary angiography in patients with moderate chronic renal failure.
近期研究表明,口服乙酰半胱氨酸对慢性肾衰竭患者预防碘造影剂所致肾毒性可能具有预防作用。在2001年6月至2002年9月期间,我们选取了120例基础血浆肌酐水平大于1.36mg/dl且接受冠状动脉造影检查的患者。治疗组包括60例患者,他们在检查前一天的早晚各接受600mg乙酰半胱氨酸,并同时进行静脉生理盐水水化。对照组患者仅接受水化治疗。两组的临床特征以及基础血浆肌酐水平具有可比性:乙酰半胱氨酸组为2.01±1.1mg/dl,对照组为1.81±0.69mg/dl。在冠状动脉造影后24小时和48小时测量血浆肌酐水平。乙酰半胱氨酸组在24小时和48小时血浆肌酐水平的相应变化分别为0.12±0.29和0.02±0.29mg/dl,对照组分别为0.06±0.29和0.07±0.43mg/dl(无显著差异)。造影剂所致急性肾衰竭定义为血浆肌酐水平较基础值升高25%,乙酰半胱氨酸组有3例患者发生,对照组有2例患者发生。急性肾衰竭的唯一预测因素是造影剂用量(316±141 vs 173±115ml,p<0.05)。总之,在充分水化且使用低剂量造影剂的中度慢性肾衰竭患者中,造影剂所致急性肾衰竭较为罕见。我们的研究未证实乙酰半胱氨酸对中度慢性肾衰竭患者冠状动脉造影后预防造影剂肾毒性具有预防作用。